Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1093/BIOSTATISTICS/KXT049 | ||||
| Año | 2014 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
We consider inference for longitudinal data based on mixed-effects models with a non-parametric Bayesian prior on the treatment effect. The proposed non-parametric Bayesian prior is a random partition model with a regression on patient-specific covariates. The main feature and motivation for the proposed model is the use of covariates with a mix of different data formats and possibly high-order interactions in the regression. The regression is not explicitly parameterized. It is implied by the random clustering of subjects. The motivating application is a study of the effect of an anticancer drug on a patient's blood pressure. The study involves blood pressure measurements taken periodically over several 24-h periods for 54 patients. The 24-h periods for each patient include a pretreatment period and several occasions after the start of therapy.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Mueller, Peter | Hombre |
Univ Texas Austin - Estados Unidos
The University of Texas at Austin - Estados Unidos |
| 1 | Muller, Peter | Hombre |
The University of Texas at Austin - Estados Unidos
|
| 2 | QUINTANA-OSORIO, FRANCISCO JAVIER | Hombre |
Pontificia Universidad Católica de Chile - Chile
|
| 3 | Rosner, Gary L. | Hombre |
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins - Estados Unidos
The Sidney Kimmel Comprehensive Cancer Center - Estados Unidos |
| 4 | Maitland, Michael L. | Hombre |
UNIV CHICAGO - Estados Unidos
The University of Chicago Medicine - Estados Unidos |
| Fuente |
|---|
| NIH |
| National Cancer Institute |
| NIGMS |
| National Institute of General Medical Sciences |
| NCI |
| National Center for Research Resources |
| NCRR |
| ASCO Young Investigator Award |
| University of Chicago Cancer Research Center NIH |
| A Cancer and Leukemia Group B Foundation Oncology Fellow Clinical Research Award |
| Agradecimiento |
|---|
| Peter Muller was partially funded by grant NIH-CA075981. Gary L. Rosner was partially funded by grants NIH-CA075981 and NIH P30 CA006973. Fernando A. Quintana was partially funded by grant FONDECYT 1100010. Michael L. Maitland and the primary study were funded by: A Cancer and Leukemia Group B Foundation Oncology Fellow Clinical Research Award, an ASCO Young Investigator Award, NIGMS 5T32GM007019-31 Training in Clinical Therapeutics, NCI K23CA124802 Mentored Career Development Award; NCRR M01-RR000055 administered by the University of Chicago General Clinical Research Center; and a protocol-specific grant from the University of Chicago Cancer Research Center NIH P30-CA014599. |